12 septiembre 2013

Zeltia SA : PharmaMar Announces Top line Results for PM01183 Phase II trial in Patients with Platinum Resistant/Refractory Ovarian Cancer .

*.- PharmaMar Announces Top line Results for PM01183 Phase II trial in Patients with Platinum Resistant/Refractory Ovarian Cancer .

*.- 30.3% of patients with platinum resistant disease responded to treatment with PM01183, while no patients in the topotecan arm responded .

*.- 82% of patients with platinum resistant disease treated with PM01183 compared to 50% of patients treated with topotecan exhibited a clinical benefit .

*.- The median progression-free survival (PFS) in resistant disease was 4.8 months for PM01183 and 1.7 months for topotecan (p=0.0004) .

*.- Although survival data is not yet mature, a significant increase in overall survival was observed in patients treated with PM01183 compared to topotecan .

...